Michael Austwick is Director at Verona Pharma plc (VRNA). They have made 1 open-market trade across 1 company since 2025, most recently 2025-10-07.
CIK 0002009903
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VRNA | 72,000 | $7.7M |
Shares reported on the most recent Form 4, priced at the 2025-10-08 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VRNA | SELL | 2025-08-01 | 2025-08-05 | $13.14 | $297K | +0.0% | +0.9% | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.